Buy Rating Affirmed for Vor Biopharma on Clinical Progress and Market Potential

14d ago, source: Business Insider

Begin your TipRanks Premium journey today. Vor Biopharma (VOR) Company Description: Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with ...

Deal watch: Biopharma M&A more than doubled in Q1

4d ago, source:

Mergers and acquisitions are on the rise in 2024, sending a hopeful sign for the recovery of the life sciences market. Check ...

BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals

2d ago, source: Buy

Tarsus, a Californian biopharmaceutical company, currently markets its Xdemvy treatment for demodex blepharitis which in 2023 generated net sales of USD14.7 million. Alongside this, Tarsus is ...

Biopharma deal and M&A values continue fluctuations in Q1

3d ago, source: BioWorld

In the initial quarter of 2024, biopharma deal value totaled $43.99 billion, surpassing the values of two quarters last year and falling short of two others. Biopharma M&As, meanwhile, reached $50.06 ...

ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024

on MSN ago, source:

ARCA biopharma (NASDAQ:ABIO) just reported results for the first quarter of 2024. ARCA biopharma reported earnings per share of -14 cents. The company did not report any revenue for the quarter.

Cue Biopharma Inc (CUE) Shares Down Despite Recent Market Volatility

16d ago, source: newsheater

To wrap up, the performance of Cue Biopharma Inc (CUE) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock ...

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

8d ago, source:

FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) ('Company'), a clinical-stage ...